Renalytix Share Discussion Threads

[mr roper] 03/8/2020 19:49

According to the Nasdaq it is already

[busterdog2] 03/8/2020 19:46

Got to be worth over £6 here hasn't it?

[74tom] 03/8/2020 19:46

Nice one Nimbo, that's a very nice RNS from Bio-Techne, they really know how to present the facts in a positive manner & I'm delighted to see an early August release date. Given the degree of international collaboration on the original Mount Sinai test, it provides a sense of hope that this might make a significant difference...

"The launch of a RUO version of the COVID-19 serology test brings to the research community what we believe is the highest quality SARS-CoV-2 antibody assay available," commented Dave Eansor, Bio-Techne's Protein Sciences Segment President. "The assay supports the life cycle of COVID-19 vaccine development, providing researchers with an objective way of measuring antibody titer."

And NASDAQ reacting positively unlike the walkdown we saw on AIM!

[mr roper] 03/8/2020 19:34

It’s above$16 now, nimbo. Looking good for tomorrow

[nimbo1] 03/8/2020 19:30

surely mm's will be raising the price here tomorrow. come on nasdaq pull your finger out and consolidate above $16 please.

hxxps://investors.bio-techne.com/press-releases/detail/201/bio-techne-and-kantaro-biosciences-to-launch-a-quantitative

this is the biotech news release for the research test

MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available for research use in early August. ...

[74tom] 03/8/2020 16:21

Didn’t seem to deter GAN & the directors there had some substantial holdings - as Toffeeman says if it doubles the share price then it becomes an irrelevance...?

[toffeeman] 03/8/2020 16:09

If it goes up by more that 40% then IDGAS :)

[nimbo1] 03/8/2020 16:07

Im not convinced thats right - key advantage of aim is the inheritance tax stuff. Would mr mills like it to loose that status on purpose? (I don't even know if he has kids but must be a consideration for some of the large holders)...perhaps you loose it dual listed anyway. just don't know.

[mr roper] 03/8/2020 15:14

Yup, think you may well be right.

[74tom] 03/8/2020 15:12

Yes, unsurprisingly looking a lot stronger over there vs the measly 1.7% increase on AIM / 22k volume.

You'd have to wonder how long they will remain dual listed given the complete lack of interest on UK markets. The 'Global' offering provided a strong indication in my opinion; out of 12m shares placed, only 30k were outside America. Surely this was this was just a nominal amount to satisfy regulatory requirements? Strongly suspect RENX won't be on AIM in 12 months time...

[mr roper] 03/8/2020 15:03

New high of $16.13 pinged earlier

[mr roper] 03/8/2020 15:01

Up 6% Stateside so far

[74tom] 03/8/2020 08:59

Yes @Nimbo1, I think you’re right regarding it being tangible evidence of the medical centres which will be first to adopt KidneyIntelX. As usual it seems to have been completely lost on the UK market!

It’s also clear evidence that Covid-19 has significantly increased the Total Addressable Market for KidneyIntelX - and it was already huge.

“-- Approximately 20% to 45% of patients hospitalized with COVID-19 in the United States and over 60% of patients admitted to the ICU for COVID-19 in the United States experience acute kidney injury (AKI) , approximately 25% to 45% of whom require acute dialysis;(4)“

These stats also beg the question of whether Covid-19 increases the future risk of AKI for anyone who contracts Covid-19, regardless of whether they are initially hospitalised...

Essentially, the requirement for rapid roll out of KidneyIntelX has become more urgent

[wan] 03/8/2020 07:52

In 'any regard' this is a very important development/study.

From a commercial aspect and to summarise -

"Initial research findings are expected to be reported in late 2020, with the goal of launching KidneyIntelX commercialization activities in this COVID-19 population targeted for H1 2021."

It is obviously a large multi-centre study, so one assumes that the following Mount Sinai test availability will require it to be manufactured at a reasonable scale -

"In addition, Mount Sinai Health System's high-performance serologic SARS-CoV-2 testing will be used to assess a patient's antibody levels to COVID-19 over time, providing valuable insights into the interaction between immune response and kidney-related complications in this patient population."

This 'appears' to fit with Kantaro's goal of making the quantitative SARS-CoV-2 IgG antibody RUO kit (based on the Mount Sinai assay) available in August 2020 at scale.

[mr roper] 03/8/2020 07:45

Yup. Agree. Good to see a bit of covid bingo as well. Should bring some additional investor attention Stateside.

[nimbo1] 03/8/2020 07:12

Best thing about this is the involvement of some top medical centres / networks...doesnt take a lot of imagination to guess where kidney intel x will be rolled out commercially post Mount Sinai installation imo.

[mr roper] 31/7/2020 14:50

Yup, liked the following line and last two forwards in particular. Suspect they are pretty close..

“Kantaro has partnered with Bio-Techne to create a strong, consistent supply chain for tests, with the goal of making the research kits available in August 2020 at scale“

[nimbo1] 31/7/2020 14:16

When they first announced the test (like everyone) they stated they were attempting to do in about 4-6 weeks what normally takes 2 years! On that basis I always thought July too optimistic - its fantastic to have confirmation all is moving forward with it. I've never really factored it into my valuations but perhaps its actually worth something :)

[74tom] 31/7/2020 11:15

I’m impressed with the website update, lots of new information & they are marketing the benefits of their test vs more generic antibody in an assertive but professional manner.

It’s certainly going to be a tasty RNS when they release it as we’ve seen very recently the impact that any Covid related news has on US listed shares; yesterday Precipio announced a worldwide distribution agreement that saw it’s price rise by 500%



In my opinion our test is significantly further forward via the involvement of Bio Techne & therefore can scale a lot faster. If nothing else it’ll put us on the radar of far more US investors - maybe similar to the impact Covid has had on AVCT?

[mr roper] 31/7/2020 08:03

August next week so not long to wait really.

[wan] 31/7/2020 08:02

I am not despondent in the slightest, testing has continued via Mount Sinai and is up significantly on the the previously reported 30,000, which will provide an important and possibly unique data set. So this test will have amazing data supporting it, already demonstrating its utility will be extended -

Proven
"During the COVID-19 outbreak in New York, Mount Sinai successfully used the underlying serologic assay that is now in the Kantaro kit over 50,000 times, establishing a deep and diverse data set."

"As of June 2020, Mount Sinai has successfully used the antibody testing technology now found in the Kantaro kit over 50,000 times across a highly diverse population."

And the test for vaccine developement will come earlier in August

[2theduke] 31/7/2020 07:22

Yes I’ve been looking every day at kantaro and today was crunch day to update the July text.
Well it’s not ideal but I suppose it’s another 4 weeks only.

[wan] 31/7/2020 05:52

Kantaro Bio link added to header.

[wan] 31/7/2020 05:41

The Kantaro website has been updated in several areas, and as suspected the antibody test availability has been delayed, with the 'patient version' expected to be available at the end of August. However, there does appear to have been important progress as they state that the COVID-SeroIndex™, which is FDA cleared (presumably based on the Mount Sinai version granted EUA in April), is for vaccine developers and will hopefully be available at scale during August 2020 -



I note that because Kantaro’s antibody test allows you to monitor the amount of antibodies you have, patients are encouraged to test more than once -

Antibody Test Kits
We thank you for your interest in Kantaro’s SARS-CoV-2 IgG Antibody Test Kit. The test is expected to be available by the end of August. Please discuss with your physician about ordering a test from your local testing facility.

Kantaro’s groundbreaking COVID-19 antibody tests will tell you the number of antibodies you have, making for more accurate, reliable and measurable results so you can manage your health and well-being.

Accurate
Unlike most other tests, which just tell you whether you are positive/negative for COVID-19 antibodies, Kantaro’s test tells you the number of potentially neutralizing (anti-virus) antibodies in your system, which can give you a more precise. understanding of your health and well-being, including your likelihood of re-infection.

Knowing the amount of anti-virus antibodies you have — your antibody number — is the first step towards an informed future for you, your family and your community.

Proven
Mount Sinai developed the technology underlying Kantaro’s kits during the height of the COVID-19 outbreak in New York City, designing the test to set the standard in antibody testing.

As of June 2020, Mount Sinai has successfully used the antibody testing technology now found in the Kantaro kit over 50,000 times across a highly diverse population.

Accessible
We believe everyone deserves access to important information about their health, so the Kantaro antibody test is designed to be easily used in laboratories all over the world.

Because Kantaro’s antibody test allows you to monitor the amount of antibodies you have, we encourage you to get our test more than once.

With your Kantaro test results, you can do your part to help the world recover from COVID-19 by donating plasma or joining our patient informational dashboard, which will speed the search for a treatment or a vaccine.

Prior to the Kantaro test being able to be ordered it is available at the Mount Sinai Health System who ask for individuals volunteering to donate convalescent plasma, as well as healthcare workers and first responders. To learn more, please visit Mount Sinai’s Convalescent Plasma Program website. If you are interested in donating plasma, please complete Mount Sinai’s COVID-19 Plasma Donation Form.



I assume that we may get some form of update accordingly.